Literature DB >> 2877398

A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma.

S H Friend, R Bernards, S Rogelj, R A Weinberg, J M Rapaport, D M Albert, T P Dryja.   

Abstract

The genomes of various tumour cells contain mutant oncogenes that act dominantly, in that their effects can be observed when they are introduced into non-malignant cells. There is evidence for another class of oncogenes, in which tumour-predisposing mutations are recessive to wild-type alleles. Retinoblastoma is a prototype biological model for the study of such recessive oncogenes. This malignant tumour, which arises in the eyes of children, can be explained as the result of two distinct genetic changes, each causing loss of function of one of the two homologous copies at a single genetic locus, Rb, assigned to the q14 band of human chromosome 13. Mutations affecting this locus may be inherited from a parent, may arise during gametogenesis or may occur somatically. Those who inherit a mutant allele at this locus have a high incidence of non-ocular, second tumours, almost half of which are osteosarcomas believed to be caused by the same mutation. Here we describe the isolation of a complementary DNA segment that detects a chromosomal segment having the properties of the gene at this locus. The gene is expressed in many tumour types, but no RNA transcript has been found in retinoblastomas and osteosarcomas. The cDNA fragment detects a locus spanning at least 70 kilobases (kb) in human chromosome band 13q14, all or part of which is frequently deleted in retinoblastomas and osteosarcomas.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877398     DOI: 10.1038/323643a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  661 in total

Review 1.  Molecular genetics of ovarian cancer.

Authors:  A N Shelling; W Foulkes
Journal:  Mol Biotechnol       Date:  2001-09       Impact factor: 2.695

Review 2.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

3.  Clefts, grooves, and (small) pockets: the structure of the retinoblastoma tumor suppressor in complex with its cellular target E2F unveiled.

Authors:  Karl Munger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-26       Impact factor: 11.205

Review 4.  RNA polymerase III transcription: its control by tumor suppressors and its deregulation by transforming agents.

Authors:  T R Brown; P H Scott; T Stein; A G Winter; R J White
Journal:  Gene Expr       Date:  2000

5.  p53 functions as a cell cycle control protein in osteosarcomas.

Authors:  L Diller; J Kassel; C E Nelson; M A Gryka; G Litwak; M Gebhardt; B Bressac; M Ozturk; S J Baker; B Vogelstein
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

6.  Immunohistochemical study of Cell Cycle Modulators in G(1)-S Transition in Clinical Breast Cancer Tissue.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

7.  Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma.

Authors:  V Greger; E Passarge; W Höpping; E Messmer; B Horsthemke
Journal:  Hum Genet       Date:  1989-09       Impact factor: 4.132

8.  Retinoblastoma gene product as a downstream target for a ceramide-dependent pathway of growth arrest.

Authors:  G S Dbaibo; M Y Pushkareva; S Jayadev; J K Schwarz; J M Horowitz; L M Obeid; Y A Hannun
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

9.  Inhibition of Wnt/β-catenin by anthelmintic drug niclosamide effectively targets growth, survival, and angiogenesis of retinoblastoma.

Authors:  Zhi Li; Qin Li; Genguo Wang; Yi Huang; Xiaochun Mao; Yanfang Zhang; Xueyan Wang
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

10.  Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130.

Authors:  Jan-Hermen Dannenberg; Leontine Schuijff; Marleen Dekker; Martin van der Valk; Hein te Riele
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.